Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Ikoma J, Kakehashi R, Kojima Y, Suzuki S
Third Department of Internal Medicine, Mie University School of Medicine, Japan.
J Hepatol. 1992 Sep;16(1-2):138-44. doi: 10.1016/s0168-8278(05)80106-0.
To evaluate the effect of interferon-alpha treatment on the levels of serum aminotransferase (sALT) and of hepatitis C virus (HCV)-RNA, we studied 19 patients with chronic non-A, non-B (NANB) hepatitis. Before therapy, 14 patients were positive by nested polymerase chain reaction (PCR) with primers deduced from the 5'-non-coding region of the HCV genome. Serum HCV-RNA had disappeared in 12 (85.7%) of them by the end of therapy, but then reappeared 6 months later in 4 of these 12 patients. A marked improvement in sALT was seen in 5 of the 8 patients with sustained HCV-RNA disappearance, but not in the 4 patients with only transient HCV-RNA negativity. Pre-treatment levels of hepatitis C viremia, analyzed by single PCR and dot blot hybridization, ranged from 2 x 10(3) to 2 x 10(8) copies/ml, and were below 2 x 10(5) copies/ml in patients with a complete response to interferon therapy. These results suggest that this HCV-RNA assay, combined with sALT testing, may be useful for estimation of the long-term efficacy of interferon therapy in hepatitis C.
为评估α-干扰素治疗对血清转氨酶(sALT)水平及丙型肝炎病毒(HCV)-RNA水平的影响,我们研究了19例慢性非甲非乙型(NANB)肝炎患者。治疗前,14例患者采用从HCV基因组5'-非编码区推导的引物进行巢式聚合酶链反应(PCR)检测呈阳性。治疗结束时,其中12例(85.7%)患者血清HCV-RNA消失,但6个月后这12例患者中有4例再次出现。8例HCV-RNA持续消失的患者中有5例sALT明显改善,而4例仅HCV-RNA短暂转阴的患者则无此改善。通过单PCR和斑点印迹杂交分析,治疗前丙型肝炎病毒血症水平为2×10³至2×10⁸拷贝/ml,对干扰素治疗完全应答的患者其水平低于2×10⁵拷贝/ml。这些结果提示,这种HCV-RNA检测方法结合sALT检测,可能有助于评估干扰素治疗丙型肝炎的长期疗效。